Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline Review, H2 2016’, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

The report reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics and enlists all their major and minor projects

The report assesses Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Destiny Pharma Ltd

Galapagos NV

MGB Biopharma Ltd

Syntiron LLC

Techulon Inc

Valevia UK Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview 7

Therapeutics Development 8

Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview 8

Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 9

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Development by Companies 10

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 11

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Development by Companies 14

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Investigation by Universities/Institutes 15

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development 16

Destiny Pharma Ltd 16

Galapagos NV 17

MGB Biopharma Ltd 18

Syntiron LLC 19

Techulon Inc 20

Valevia UK Ltd 21

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

acALY-18 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

exeporfinium chloride - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

GLPG-1492 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

MGBBP-3 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

MH-003 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Siderocillin - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Staphylococcus aureus vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

VAL-301 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects 43

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products 44

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones 45

Featured News & Press Releases 45

Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 4

List of Tables

List of Tables

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2016 8

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Destiny Pharma Ltd, H2 2016 16

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Galapagos NV, H2 2016 17

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by MGB Biopharma Ltd, H2 2016 18

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Syntiron LLC, H2 2016 19

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Techulon Inc, H2 2016 20

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Valevia UK Ltd, H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Dormant Projects, H2 2016 43

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Discontinued Products, H2 2016 44

List of Figures

List of Figures

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2016 8

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports